Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

The Genomic Landscape of Myeloproliferative Neoplasms: Somatic Calr Mutations in the Majority of JAK2-Wildtype Patients

Jyoti Nangalia, MBBChir FRCPath, Charles Massie, PhD, E Joanna Baxter, PhD, Francesca L Nice, MRes, Gunes Gundem, PhD, David Wedge, PhD, Edward Avezov, PhD, Juan Li, PhD, Karoline Kollmann, PhD, David G. Kent, PhD, Athar Aziz, PhD, Anna L Godfrey, BMBCh FRCPath, Jonathan Hinton, MSc, Inigo Martincorena, PhD, Peter Van Loo, PhD, Amy V Jones, PhD, Paola Guglielmelli, PhD MD, Patrick Tarpey, PhD, Heather P Harding, PhD, John D Fitzpatrick, BA, Calum T Goudie, BA, Christina A Ortmann, MD, Stephen J Loughran, PhD, Keiran Raine, MSc, David Jones, MSc, Adam Butler, MSc, Jon W Teague, MSc, Sarah O'Meara, Stuart McLaren, Michele Bianchi, Yvonne Silber, MSc, Danai Dimitropolou, BSc, David Bloxham, MSc FRCPath, Laura J Mudie, BSc, Mark Maddison, BSc, Ben Robinson, BSc, Clodagh Keohane, MD, Cathy MacLean, MSc, Kate Hill, BM BS, Kim H. Orchard, MBBS, PhD, FRCP, FRCPath, Sudhir Tauro, PhD, Ming-Qing Du, MB, PhD, Mel Greaves, PhD, FRS, David Bowen, MD, PhD, Brian Huntly, MBChB FRCPath PhD, Claire N Harrison, DM, FRCP, FRCPath, Nicholas C.P. Cross, PhD, FRCPath, David Ron, MD, Alessandro M Vannucchi, MD, Elli Papaemmanuil, PhD, Peter J. Campbell, PhD, Anthony R Green, FRCPath FMedSci

Blood (2013) 122 (21): LBA-2.

https://doi.org/10.1182/blood.V122.21.LBA-2.LBA-2

Published: 2013

Journal Articles

Latent Myeloproliferative Neoplasm May Underlie Retinal Vein Occlusion In Older Patients

Katerina Zoi, PhD, Christine Zoi, Andreas Giannopoulos, MSc, Argyri Gialeraki, PhD, Kassiani Giannaki, MD, PhD, Niki Rougkala, Panagiotis Theodosiadis, MD, John Vergados, MD, Dimitris Loukopoulos, Nicholas C.P. Cross, PhD, FRCPath, Marianna Politou

Blood (2013) 122 (21): 5242.

https://doi.org/10.1182/blood.V122.21.5242.5242

Published: 2013

Journal Articles

Recurrent SETBP1 Mutations in Atypical Chronic Myeloid Leukemia Abrogate an Ubiquitination Site and Dysregulate SETBP1 Protein Levels

Blood (2012) 120 (21): LBA-2.

https://doi.org/10.1182/blood.V120.21.LBA-2.LBA-2

Published: 2012

Journal Articles

Inactivation of Polycomb Repressive Complex 2 Components in Myeloproliferative and Myelodysplastic/Myeloproliferative Neoplasms

Nicholas C.P. Cross, PhD, FRCPath, Joannah Score, PhD, Claire Hidalgo-Curtis, PhD, Amy V Jones, PhD, Nils Winkelmann, MD, Alison Skinner, BSc, Daniel Ward, MSc, Katerina Zoi, MD, PhD, Thomas Ernst, MD, Frank Stegelmann, MD, Konstanze Dohner, MD, PhD, Andrew J Chase, PhD

Blood (2011) 118 (21): 617.

https://doi.org/10.1182/blood.V118.21.617.617

Published: 2011

Journal Articles

A Phase IIIb Multicentre Open-Label Study of Nilotinib in Adult Patients with Newly Diagnosed BCR-ABL Positive Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A European Clinical Initiative with EUTOS Collaboration for Standardisation of Molecular Remission

Francis J. Giles, MB, MD, FRCPI, FRCPath, Gianantonio Rosti, MD, Gert Ossenkoppele, MD, PhD, Michel Tulliez, Jesper Stentoft, MD, PhD, Aristoteles Giagounidis, MD, Francesco Nobile, MD, Philipp D. le Coutre, MD, Norbert Gattermann, MD, Laimonas Griskevicius, Nicholas C.P. Cross, PhD, FRCPath, Sarah Hill, BSc (hons), PhD, MICR, Peter Schuld, PhD, Angela Pellegrino, Domenico Magazzù, Andreas Hochhaus, MD

Blood (2011) 118 (21): 2759.

https://doi.org/10.1182/blood.V118.21.2759.2759

Published: 2011

Journal Articles

Analyses of 81 Chronic Myelomonocytic Leukemia (CMML) for EZH2 , TET2 , ASXL1 , CBL , KRAS , NRAS , RUNX1 , IDH1 , IDH2 , and NPM1 Revealed Mutations In 86.4% of All Patients with TET2 and EZH2 Being of High Prognostic Relevance

Vera Grossmann, MA, Alexander Kohlmann, PhD, Christiane Eder, PhD, Nicholas C.P. Cross, PhD, FRCPath, Claudia Haferlach, MD, Wolfgang Kern, MD, Torsten Haferlach, MD, Susanne Schnittger, PhD

Blood (2010) 116 (21): 296.

https://doi.org/10.1182/blood.V116.21.296.296

Published: 2010

Journal Articles

Harmonized Testing for BCR-ABL Kinase Domain Mutations In CML: Results of a Survey and First Control Round within 28 National Reference Laboratories In Europe

Blood (2010) 116 (21): 894.

https://doi.org/10.1182/blood.V116.21.894.894

Published: 2010

Journal Articles

KIT D816V and JAK2 V617F Point Mutations Are Recurrently Found In Suspected Hypereosinophilic Syndrome

Juliana Popa, MD, Philipp Erben, MD, Georgia Metzgeroth, MD, Georg Bolz, MD, Martin C Mueller, MD, Christoph Walz, MD, Hans Peter Horny, MD, Philipp Ströbel, MD, Alexander Marx, MD, Nicholas C.P. Cross, PhD, FRCPath, Andreas Hochhaus, Wolf-Karsten Hofmann, MD, Andreas Reiter, MD

Blood (2010) 116 (21): 4100.

https://doi.org/10.1182/blood.V116.21.4100.4100

Published: 2010

Journal Articles

Association Between EZH2 and Other Acquired Mutations In Myelofibrosis and Myelodysplastic/Myeloproliferative Neoplasms

Thomas Ernst, MD, Joannah Score, PhD, Claire E Hidalgo-Curtis, PhD, Amy V Jones, PhD, Andreas Hochhaus, MD, Dolors Colomer, MD, Francisco Cervantes, MD, Andrew J Chase, PhD, Nicholas C.P. Cross, PhD, FRCPath

Blood (2010) 116 (21): 625.

https://doi.org/10.1182/blood.V116.21.625.625

Published: 2010

Journal Articles

The JAK2 46/1 Haplotype Predisposes to Myeloproliferative Neoplasms Characterized by Diverse Mutations.

Nicholas C.P. Cross, PhD, FRCPath, Peter Campbell, MD, PhD, Philip A Beer, BM, MRCP, MRCPath, Susanne Schnittger, PhD, Alessandro M. Vannucchi, MD, Katerina Zoi, PhD, Melanie Percy, PhD, FRCPath, Mary Frances McMullin, Linda Scott, BSc, PhD, Richard T. Silver, MD, David Oscier, MD, Claire Harrison, MD, Anthony R. Green, FRCP, FRCPath, FMed, Sci, Andrew Chase, PhD

Blood (2009) 114 (22): 433.

https://doi.org/10.1182/blood.V114.22.433.433

Published: 2009

NARROW

The Genomic Landscape of Myeloproliferative Neoplasms: Somatic Calr Mutations in the Majority of JAK2-Wildtype Patients

Latent Myeloproliferative Neoplasm May Underlie Retinal Vein Occlusion In Older Patients

Recurrent SETBP1 Mutations in Atypical Chronic Myeloid Leukemia Abrogate an Ubiquitination Site and Dysregulate SETBP1 Protein Levels

Inactivation of Polycomb Repressive Complex 2 Components in Myeloproliferative and Myelodysplastic/Myeloproliferative Neoplasms

A Phase IIIb Multicentre Open-Label Study of Nilotinib in Adult Patients with Newly Diagnosed BCR-ABL Positive Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A European Clinical Initiative with EUTOS Collaboration for Standardisation of Molecular Remission

Analyses of 81 Chronic Myelomonocytic Leukemia (CMML) for EZH2 , TET2 , ASXL1 , CBL , KRAS , NRAS , RUNX1 , IDH1 , IDH2 , and NPM1 Revealed Mutations In 86.4% of All Patients with TET2 and EZH2 Being of High Prognostic Relevance

Harmonized Testing for BCR-ABL Kinase Domain Mutations In CML: Results of a Survey and First Control Round within 28 National Reference Laboratories In Europe

KIT D816V and JAK2 V617F Point Mutations Are Recurrently Found In Suspected Hypereosinophilic Syndrome

Association Between EZH2 and Other Acquired Mutations In Myelofibrosis and Myelodysplastic/Myeloproliferative Neoplasms

The JAK2 46/1 Haplotype Predisposes to Myeloproliferative Neoplasms Characterized by Diverse Mutations.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only